The abstract is read at the publisher; the summary is JClub's.
S-023-0996 (41a) is a tumor cell-selective dual EZH2-EGFR inhibitor that more efficiently suppresses TNBC tumor growth and metastasis in preclinical models than EZH2+EGFR drug combinations.
- Why it matters: TNBC has limited targeted options, and database analyses link concomitant EZH2 and EGFR overexpression to poor survival, motivating dual-pathway inhibition.
- What they did: Potent probes were designed to bind both EZH2 and EGFR, and SAR optimization produced S-023-0996 (41a), which inhibited proliferation, migration, and invasion in vitro. Mass spectrometry proteomics indicated translation inhibition as a key differentiator, and in vivo testing assessed tumor growth and metastasis versus tazemetostat+gefitinib.
- The result: S-023-0996 (41a) showed superior efficacy and safety to individual drug combinations in vitro and more efficient anti-tumor and anti-metastatic effects in vivo, supporting a first-in-class dual EZH2-EGFR strategy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.